BioCatalyst

LY3650150, Standard therapy for INCS — catalyst calendar

1 verified catalyst event(s) referencing LY3650150, Standard therapy for INCS, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09 (month)
in 2mo
ESTIMATED
 READOUT
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (
Phase 3 · Perennial Allergic Rhinitis (PAR)
 LLY ELI LILLY & Co LY3650150, Standard therapy for INCS ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.